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Abstract
The enzyme methionine aminopeptidase-2 (MetAP-2) is thought
to play an important function in human endothelial cell
proliferation, and as such provides a valuable target in both
inflammation and cancer. Rheumatoid arthritis (RA) is a chronic
inflammatory disease associated with increased synovial
vascularity, and hence is a potential therapeutic target for
angiogenesis inhibitors. We examined the use of PPI-2458, a
selective non-reversible inhibitor of MetAP-2, in disease models
of RA, namely acute and chronic collagen-induced arthritis (CIA)
in mice. Whilst acute CIA is a monophasic disease, CIA induced
with murine collagen type II manifests as a chronic relapsing
arthritis and mimics more closely the disease course of RA. Our
study showed PPI-2458 was able to reduce clinical signs of
arthritis in both acute and chronic CIA models. This reduction in
arthritis was paralleled by decreased joint inflammation and
destruction. Detailed mechanism of action studies
demonstrated that PPI-2458 inhibited human endothelial cell
proliferation and angiogenesis in vitro, without affecting
production of inflammatory cytokines. Furthermore, we also
investigated release of inflammatory cytokines and chemokines
from human RA synovial cell cultures, and observed no effect of
PPI-2458 on spontaneous expression of cytokines and
chemokines, or indeed on the angiogenic molecule vascular
endothelial growth factor (VEGF). These results highlight
MetAP-2 as a good candidate for therapeutic intervention in RA.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease
that is characterized by severe synovial inflammation, resulting
in destruction of bone and cartilage. At the cellular level, early
changes in the RA synovium include angiogenesis, inflamma-
tory cell infiltration and synovial hyperplasia. Angiogenesis is
defined as the process in which blood vessels form by the
sprouting of pre-existing capillary plexuses [1]. It is a complex,
highly regulated process found in physiological settings such
as wound and fracture healing and during the female repro-
ductive cycle. Otherwise, the vascular endothelium is main-
tained in a state of quiescence, which is the result of a tightly
regulated system of opposing angiogenic regulators [2].
Angiogenesis is now also recognized to be a fundamental
component of disease progression in RA [3]. Synovial blood
vessel number has been found to correlate with hyperplasia,
mononuclear cell infiltration and indices of joint tenderness
[4]. Endothelial cells lining blood vessels within RA synovium
have been shown to express cell cycle antigens such as
PCNA (proliferating cell nuclear antigen) and Ki67 [5]. In the
inflamed synovium, the normally quiescent angiogenic balance
CIA = collagen-induced arthritis; ELISA = enzyme-linked immunosorbent assay; FCS = foetal calf serum; FGF = fibroblast growth factor; HUVEC = 
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is disrupted in favour of angiogenesis by upregulated produc-
tion of a variety of angiogenic stimulators, including vascular
endothelial growth factor (VEGF) [6,7]. VEGF has been
detected at higher levels in serum and synovial fluid from RA
patients [8]. However, although blockade of VEGF has been
proposed to be of potential therapeutic benefit in RA, emerg-
ing understanding of other potential functions of VEGF are
making this molecule less attractive as a therapeutic target in
the clinic. For example, reduced expression of VEGF has been
reported to result in amyotrophic lateral sclerosis-like motor
neurone degeneration in mice, suggesting a neuroprotective
role for VEGF [9]. Thus, despite the considerable success of
VEGF blockade in colorectal cancer, complications associ-
ated with anti-VEGF antibody, such as hypertension and gas-
trointestinal perforation, have prompted the search for other
angiogenesis-associated targets.
Methionine aminopeptidase (MetAP)-2 is a metalloprotease
that plays a key role in the removal of amino-terminal initiator
methionines from nascent polypeptides [10]. The MetAP
enzymes have been divided into two classes, with the MetAP-
2 isoform being identified as the protein that irreversibly bound
the angiostatic compounds fumagillin and its derivative AGM-
1470/TNP-470 [11]. Previous reports have shown that fum-
agillin and AGM-1470/TNP-470 primarily function by inhibit-
ing cell proliferation [11,12], and it has therefore been
suggested that irreversible inhibition of MetAP-2 catalytic
activity accounts for at least part of the anticancer action of
such compounds [13-15]. Specifically, AGM-1470/TNP-470
has been reported to prevent the entry of endothelial cells into
the G1 phase of the cell cycle [16]. A reversible MetAP-2 inhib-
itor was also reported to lead to endothelial cell cycle arrest
and to exhibit efficacy in a range of murine tumour models [17].
Other MetAP-2 inhibitors have been described as inhibiting
tumour growth in mice, and to induce accumulation in
endothelial cells of the cyclin-dependent kinase inhibitor
p21WAF1/Cip1 [18].
It has been reported that fumagillin and other molecules that
may act by inhibiting MetAP-2 reduce arthritis in animal mod-
els. In these models, disease is induced by immunizing sus-
ceptible strains of mice with collagen to generate an
autoimmune response similar to that of RA, which includes
inflammation at joints and joint destruction. Such collagen-
induced arthritis (CIA) is in widespread use as a model of
arthritis, and provides a useful tool with which to study the
pathology of arthritis. We and others have shown that inhibi-
tion of angiogenesis, using either approaches targeting VEGF
or other antiangiogenic strategies, ameliorates disease [19-
25].
In the present study we utilized CIA to investigate further the
therapeutic potential in RA of PPI-2458, an irreversible
MetAP-2 inhibitor based on the fumagillin class of com-
pounds. Our in vivo studies contained two models of arthritis
with induction of CIA by bovine or murine collagen. When
bovine collagen type II was used, the resultant disease was
monophasic and characterized by severe synovial inflamma-
tion resulting in destruction of bone and cartilage. Disease
severity was markedly reduced by PPI-2458. In addition to
assessing the effects of PPI-2458 in acute CIA, we examined
the effect of PPI-2458 in a model of chronic relapsing arthritis.
We observed that PPI-2458, as well as reducing acute CIA,
significantly decreased disease severity and joint destruction
in chronic relapsing CIA. A potential mechanism of action of
PPI-2458  in vivo was through reduction in angiogenesis,
because in vitro studies showed endothelial proliferation and
angiogenesis was inhibited by PPI-2458 whereas endothelial
inflammatory responses were not affected. Similarly, release of
tumour necrosis factor (TNF)-α, IL-6, and the chemokines IL-8,
interferon-γ-inducible protein (IP)-10, macrophage inflamma-
tory protein (MIP)-1α and monocyte chemoattractant protein
(MCP)-1 by human RA synovial membrane cells remained
unaffected. These findings provide support for the concept
that blockade of MetAP-2 may be an effective approach to
treatment of RA.
Materials and methods
Induction and monitoring of heterologous and 
homologous CIA
Bovine type II collagen was extracted from bovine articular car-
tilage and murine type II collagen was purified from mouse
sternums. Purification was carried out as previously described
[26].
For induction of acute heterologous CIA, 10-week-old male
DBA/1 (H-2q) mice (Harlan UK Limited, Oxon, UK) received a
single intradermal injection at the base of the tail of 100 μg
bovine type II collagen emulsified in Freund's complete adju-
vant, containing paraffin oil, and lyophilized Mycobacterium
tuberculosis  H37 Ra (Difco Becton Dickinson, Cowley,
Oxford, UK). The first clinical signs of arthritis were deemed to
be present when oedema and/or erythema involving any one
of the four paws was observed. Onset of disease was
observed from 2 weeks after collagen administration. For
induction of chronic homologous CIA, 8-week-old DBA/1 (H-
2q) male mice were used (Harlan UK Limited) and immunized
following a protocol adapted from the previously described
model [27], using an intradermal injection at the base of the tail
of 100 μg murine type II collagen emulsified in Freund's com-
plete adjuvant followed by a boost of 100 μg of murine type II
collagen given at day 14. The first clinical signs of arthritis
were assessed as for acute CIA, with onset of disease occur-
ring from 2 weeks after murine type II collagen boost.
In both models mice were monitored daily and each limb was
assigned a clinical score as follows: 0, normal paws and no
clinical features of inflammation; 1, slight oedema or erythema;
2, pervading oedema/erythema involving the entire paw; and
3, pronounced oedema and erythema leading to incapacitatedAvailable online http://arthritis-research.com/content/9/6/R127
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limb mobility. All mice used in this study were housed in indi-
vidual ventilated cages over a 20-hour light/dark cycle and
were fed standard laboratory chow and water ad libitum. Ani-
mal work was conducted under the Home Office project
licence PPL no: 70/5446 'Pathogenesis and therapy for RA'
under the operatives of the Animals (Scientific Procedures)
Act 1986, which followed the principles of the Helsinki
Declaration.
In both models, animals were treated with PPI-2458 [28], a
member of the fumagillin class of antiantigenic compounds.
Fumagillin and its analogues are reported to be potent, irre-
versible and selective inhibitors of MetAP-2 [29]. PPI-2458
was synthesized by the method covered in the Praecis Phar-
maceuticals patent WO 02/42295 2002, priority US 704251
2000. The structure of the molecule is shown in Figure 1.
Treatments were administered from the first day of visible
arthritis. Mice with acute CIA were treated daily intraperito-
neally with vehicle control (saline) or PPI-2458 at 0.5 mg/kg,
1.5 mg/kg, or 5 mg/kg for 10 days. For chronic CIA, treat-
ments were every other day intraperitoneally as follows: vehi-
cle (sterile 0.85% physiological saline), murine soluble TNF
receptor (murine p75 receptor dimer fused to murine IgG2a;
soluble TNF receptor [sTNF-R]II) at 5 mg/kg, PPI-2458 at 1.5
mg/kg and indomethacin (Sigma Aldrich Co., Poole, UK) at
2.5 mg/kg. Two chronic CIA experiments were performed,
with the first terminated 4 weeks after onset of symptoms (day
29 of arthritis) and the second terminated 10 weeks after
onset of symptoms (day 71 of arthritis).
Histopathology
At the end of the experiments the hind feet of mice were
excised after euthanasia and fixed in 10% buffered formalin
solution. Fixed specimens were decalcified (Rapid-Cal™; BBC
Biochemical, Dallas, TX, USA) and embedded in paraffin wax.
Serial sections of 5 μm thickness were obtained, dewaxed,
and stained with haematoxylin and eosin. The stained sections
were scored microscopically for changes to joint architecture
by an observer who was blinded to the study groups. Paws
were assigned one of four grades: normal; mild synovitis with
some loss of cartilage; moderate with more extensive synovial
hyperplasia, destruction of cartilage and some bone erosions
caused by an invasive pannus front; and finally severe, namely
to have complete destruction of the joint architecture. Data
were analysed by χ2 test comparison of the number of animals
exhibiting normal, mild, moderate and severe changes versus
untreated mice.
Endothelial cell studies
Human umbilical cords were collected from Chelsea and
Westminster Hospital (London, UK) in accordance with the
guidelines of the Riverside Research Ethics Committee
(RREC 2948). Human umbilical vein endothelial cells
(HUVEC) were isolated by digestion of umbilical cord veins in
0.025 mg/ml collagenase A (Roche Diagnostics, Mannheim,
Germany) [30]. Cells were maintained in RPMI-1640 (Cam-
brex, Berkshire, UK) containing 10% (vol/vol) foetal calf serum
(FCS; Biowest, Nuaillé, France), 10% (vol/vol) new born calf
serum (Gibco, Paisley, UK), 5 U/ml heparin (CP Pharmaceuti-
cals, Wrexham, UK), and 15 μg/ml endothelial cell growth sup-
plement (Sigma Aldrich Co.) at 37°C, in an atmosphere of 5%
carbon dioxide and 95% air. Endothelial cells between second
and third passage were used for all experiments.
A modified assay for mitochondrial activity was used to assess
cell viability. Wells were treated with fumagillin (GSK, Steve-
nage, UK) at a concentration of 10 nmol/l or PPI-2458 (0.01
to 10 nmol/l). Following treatment as above, 0.5 mg/ml MTT
(3-[4,5-dimethyl-2-yl]-2,5-diphenyltetrazolium; Sigma Aldrich
Co.) was added to the cells overnight. Cells were lysed using
10% SDS containing 0.001 mol/l HCl and absorption was
measured after 24 hours at 620 nm using a using a Multiskan
Ascent Scanner plate reader (Thermo Labsystems, Basing-
stoke, UK).
To determine the effect of PPI-2458 on proliferation, HUVEC
were seeded at 3 × 103 cells per 30 mm2 wells (25% conflu-
ence), in RPMI-1640 containing 10% FCS, 10% new born
calf serum, 5 U/ml heparin and 15 μg/ml endothelial cell
growth supplement for 24 hours. Medium was then changed
to different conditions (as described for each experiment) for
24 hours and cells were pulsed with 0.5 μCi 3H-thymidine (GE
Healthcare, Chalfont St Giles, UK) for a further 24 hours. At
the end of the experiment, cells were subjected to three
freeze-thaw cycles before being analyzed for 3H-thymidine
incorporation using a cell harvester (Micro-96-Harvester; Ska-
tron Instruments, Corston, UK). Human recombinant VEGF
and human recombinant fibroblast growth factor (FGF)-2 were
obtained from R&D Systems (Abingdon, UK).
To analyze the effect of PPI-2458 on angiogenesis, a commer-
cially available angiogenesis kit was used (AngioKit; TCS Cell
Works, Buckingham, UK). Cultures spontaneously developed
a network of capillary-like tubules after 11 days at 37°C in 5%
carbon dioxide. Wells were treated on day 0 with VEGF (2 ng/
ml) or FGF-2 (50 ng/ml), in the absence or presence of either
Figure 1
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fumagillin (10 nmol/l) or PPI-2458 (1 to 10 nmol/l). Culture
medium was replenished after 4, 7, and 9 days, in accordance
with the manufacturer's instructions. On day 11, the medium
was aspirated and the plates were fixed at room temperature
in 70% ethanol that had been stored at -20°C. Expression of
CD31 was visualised by staining with mouse antihuman CD31
antibody (TCS Cell Works) for 60 minutes at 37°C, followed
by goat antimouse IgG alkaline phosphatase conjugate for 10
minutes at room temperature. CD31 enzyme-linked immuno-
sorbent assay (ELISA) substrate was prepared by dissolving
p-nitrophenol phosphate in Tris buffer and was added in
accordance with the manufacturer's instructions. The plate
was then read against blank wells at 405 nm using a plate
reader Multiskan Ascent plate reader (Thermo Labsystems).
Subsequently, an insoluble substrate prepared from BCIP/
NBT (5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetra-
zolium; TCS Cell Works) was added. Once the substrate was
filtered, 0.5 ml was added per well and incubated at 37°C until
tubules developed a dark colour (5 to 15 minutes). Wells were
then washed three times with distilled water and air dried
before microscopic analysis using a BH2 microscope (Olym-
pus Optical, London, UK) linked to a KY-F55BE video camera
(JVC, London, UK). Digital images were processed using Anal-
ySIS software (Soft Imaging Software, Munster, Germany).
To determine the effect of PPI-2458 on cytokine release,
HUVEC were plated at 3 × 104 in 75 mm2 wells and stimulated
for 24 hours with either IL-1β (10 ng/ml; BioSource, UK), TNF-
α (10 ng/ml; R&D Systems), or lipopolysaccharide (LPS; 500
ng/ml; from Escherichia coli 0111:B4 cell culture tested;
Sigma Aldrich Co.) in RPMI-1640 containing 10% FCS. Fum-
agillin (10 nmol/l) and PPI-2458 (0.01 to 10 nmol/l) were
added where indicated, or 0.001% dimethyl sulfoxide as a
vehicle control. Release of MCP-1 was measured by ELISA.
Briefly, mouse monoclonal antihuman C-C chemokine ligand-
2/MCP-1 IgG2b (R&D Systems) was coated onto polystyrene
microtitre plates (Nunc-Immunoplate II; BRL, Uxbridge, Mid-
dlesex, UK) at a concentration of 2 μg/ml overnight at 4°C.
After blocking with 2% bovine serum albumin in phosphate-
buffered saline, samples or MCP-1 standard (human recom-
binant MCP-1; R&D Systems) were added overnight at 4°C.
Bound MCP-1 was detected using biotinylated antihuman
MCP-1 IgG (R&D Systems) at a concentration of 25 ng/ml, fol-
lowed by streptavadin-horseradish peroxidase (Amersham Life
Sciences Ltd, Little Chalfont, UK) and 3,3',5,5'-tetramethyl-
benzidine peroxidase substrate (Kirkegaard and Perry Labora-
tories, Gaithersburg, MA, USA). The colour reaction was then
stopped with 2 mol/l H2SO4 and absorbance was read at 450
nm on a Multiskan Ascent Scanner plate reader (Thermo
Labsystems).
RA synovial cell culture studies
Synovial tissue was harvested from patients with a diagnosis
of RA, made by rheumatologists who referred patients to
Mount Vernon Hospital (Northwood, Middlesex, UK) for hand
surgery (Local Ethics Research Committee EC2003-64). Tis-
sue was washed in sterile RPMI-1640 and cut into small
pieces using sterile scissors and surgical forceps. The result-
ant tissue was then digested in Dulbecco's modified Eagle's
medium (Lonza, Wokingham, UK) containing 10% FCS, 1 g/l
collagenase (Roche Diagnostics, Mannheim, Germany) and
0.15 g/l DNAase (type IV from bovine pancreas; Sigma Aldrich
Co.) for up to 1 hour at 37°C. The disaggregated cells were
filtered through a mesh to remove debris. Cell viability was
assessed using trypan blue exclusion. Viable cells were cul-
tured at 106/ml in a volume of 125 μl in Dulbecco's modified
Eagle's medium containing 10% FCS at 37°C in 75 mm2 wells
in the absence or presence of either Fumagillin (10 nmol/l),
PPI-2458 (0.1 to 10 nmol/l), or 0.001% dimethyl sulfoxide as
vehicle control. After 24 hours, supernatants were removed,
and cytokine production was assayed using a Beadlyte
Human Multiplex Cytokine Detection System (Upstate Bio-
technology, Lake Placid, NY, USA). Samples or standards
were incubated with the cytokine capture bead suspension
array, in accordance with the manufacturers' instructions.
Beads were washed using a vacuum manifold and biotinylated
reporter antibodies were added, followed by streptavidin-phy-
coerythrin. The median fluorescence intensity of 50 beads per
cytokine was read using a Luminex 100™ (Luminex, Austin, TX,
USA) and analysed using STarStation analysis software
(Applied Cytometry Systems, Sheffield, UK).
Statistical analysis
Data were analysed using GraphPad Prism 4.03 (GraphPad
Software, San Diego, CA, USA). For CIA experiments, analy-
sis of different treatments was carried out with a two-way anal-
ysis of variance. Histology data were analysed by χ2 test. A
one-way analysis of variance with Bonferroni post-test for mul-
tiple comparisons was used to compare different groups of
data for in vitro studies. P values less than 0.05 were consid-
ered to be statistically significant.
Results
Therapeutic effect of PPI-2458 in acute and chronic 
relapsing CIA
The acute and chronic CIA murine models were used to
assess the effect of the MetAP-2 inhibitor PPI-2458 as a
potential therapeutic agent. In acute CIA, the incidence of
arthritis in each cage reached at least 80%. The earliest signs
of disease were observed on day 14 after immunization, with
a median day of arthritis onset of day 28 after immunization. In
chronic CIA there were clinical signs of arthritis in at least 70%
of animals per cage. Animals became arthritic from day 28
after primary immunisation (14 days after murine collagen type
II boost), with a median day of arthritis onset of day 49 after
immunization.
In acute CIA, the mice treated with vehicle control developed
the typical signs of acute CIA, with a rapidly progressing
monophasic disease. Both clinical score (Figure 2a) and pawAvailable online http://arthritis-research.com/content/9/6/R127
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swelling (Figure 2b) increased with time until day 8 after onset,
when a plateau was apparent. Treatment with PPI-2458 at all
three doses (0.5, 1.5 and 5 mg/kg per day) showed a signifi-
cant arrest in the development of arthritis, which was highly
statistically significant. Treatment with PPI-2458 at 0.5 mg/kg
per day was slightly less effective than treatment with either
1.5 mg/kg per day PPI-2458 (P < 0.05 versus 0.5 mg/kg per
day) or 5 mg/kg per day PPI-2458 (P < 0.05 versus 0.5 mg/
kg per day).
Chronic CIA manifested differently to the bovine type II colla-
gen induced acute CIA, and was primarily observed as
increased reddening of the paw with individual joints affected
and progressive increase in the number of involved joints, with
a milder course of disease (Figure 3). In the first instance, the
clinical score was measured over 28 days after onset. In mice
treated with vehicle (saline), the mean clinical score exhibited
a gradual increase with time (Figure 3a). A comparable pattern
was seen in a subsequent experiment, in which mice were
monitored for up to 70 days after onset (Figure 3c). Treatment
with either PPI-2458 or with murine sTNF-RII (used as a con-
trol) for comparison significantly (P < 0.001 versus vehicle-
treated animals) reduced arthritis severity in both experiments.
For example, on day 71 of chronic arthritis, untreated mice
exhibited a mean (± standard error) clinical score of 2.57 ±
0.53, as compared with 1.33 ± 0.33 and 1.28 ± 0.47 for mice
Figure 2
PPI-2458 reduces acute CIA PPI-2458 reduces acute CIA. Following onset of arthritis induced by bovine type II collagen, mice were treated with PPI-2458 (0.5, 1.5, or 5 mg/kg 
per day) or vehicle alone (n = 8 per group). (a) Change in clinical score for each animal from day 1 of arthritis and (b) paw swelling were assessed 
over a 10-day period. Data are expressed mean ± standard error. Statistical analysis was carried out using a two-way analysis of variance versus 
vehicle-treated mice: ** P < 0.01, ***P < 0.001. CIA, collagen-induced arthritis.Arthritis Research & Therapy    Vol 9 No 6    Bainbridge et al.
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treated with PPI-2458 and sTNF-RII, respectively. In the same
experiment, vehicle-treated mice exhibited a clinical score of
2.87 ± 0.53.
Area under the curve analysis demonstrated a significant
reduction in disease severity in both experiments, relative to
vehicle-treated mice (Figures 3b,d). Such analysis allowed for
additional comparison of disease severity in this model, in
which remission and relapse occurred on different days for
individual animals. In the experiment terminated on day 29 of
arthritis, the median (interquartile range) area under the curve
for vehicle-treated mice was 68.25 (range 48.25 to 94.75), as
compared with 16.50 (7.00 to 45.00) and 35.00 (28.00 to
49.00) for sTNF-RII and PPI-2458 treated animals, respec-
tively. Similarly, in the experiment terminated on day 71 of
arthritis, the median (interquartile range) area under the curve
Figure 3
PPI-2458 reduces chronic CIA PPI-2458 reduces chronic CIA. Following onset of arthritis induced by murine type II collagen, mice were treated with either PPI-2458 (1.5 mg/kg 
every other day), soluble tumour necrosis factor receptor (sTNF-R)II (5 mg/kg every other day) or vehicle alone, or were left untreated (as indicated 
for the relevant experiments). (a) Clinical score was assessed over 4 weeks. Data are expressed mean ± standard error. Statistical analysis was car-
ried out using a two-way analysis of variance versus vehicle-treated mice: ***P < 0.001. Each treatment group contained at least six mice. (b) Area 
under curve analysis, with data represented as box-and-whiskers plots. Statistical analysis was carried out using a one-way analysis of variance ver-
sus vehicle-treated mice: *P < 0.05, **P < 0.01. (c) Clinical score was assessed over 10 weeks. Data are expressed mean ± standard error. Statis-
tical analysis was carried out using a two-way ANOVA versus vehicle-treated mice: ***P < 0.001. Each treatment group contained at least eight 
mice. (d) Area under curve analysis, with data represented as box-and-whiskers plots. Statistical analysis was carried out using a one-way analysis of 
variance versus vehicle-treated mice: *P < 0.05, **P < 0.01.Available online http://arthritis-research.com/content/9/6/R127
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for untreated and vehicle-treated mice was 115.00 (97.50 to
127.30) and 114.30 (86.00 to 166.30), as compared with
62.75 (40.00 to 95.50) and 73.00 (56.00 to 95.00) for sTNF-
RII and PPI-2458 treated animals, respectively.
Analysis of chronic CIA paw histology revealed increased cel-
lular infiltrate. This was accompanied by bone loss and evi-
dence of new woven bone formation. Compared with
untreated mice, both PPI-2458-treated mice (P = 0.0015 ver-
sus untreated mice, by χ2 test) and sTNF-RII-treated mice (P
< 0.001) exhibited significant improvement in joint histology
(Figure 4 and Table 1) on day 29 of arthritis. The percentages
of animals exhibiting normal joint histology or only mild synovi-
tis were 48% and 75%, respectively, as compared with just
11% for untreated animals. In the same experiment, indometh-
acin (2.5 mg/kg every other day) treatment significantly
reduced clinical score (P < 0.001 versus untreated mice; data
not shown), but was without significant effect on joint destruc-
tion (P = 0.1074; data not shown), which is in agreement with
previously published data for this arthritis model [27]. Similarly,
39% of untreated animals killed on day 71 of arthritis exhibited
normal joint histology or only mild synovitis, as compared with
50% for sTNF-RII-treated mice (P = 0.023 versus untreated
mice) and 78% for PPI-2458-treated mice (P = 0.009; data
not shown).
Endothelial proliferation and angiogenesis are inhibited 
by PPI-2458
Treatment of HUVEC with PPI-2458 significantly inhibited pro-
liferation induced by either VEGF (Figure 5a) or FGF-2 (Figure
5b), assessed as incorporation of 3H-thymidine. PPI-2458 at 1
nmol/l was as effective as fumagillin at a dose of 10 nmol/l.
Furthermore, the effect of PPI-2458 on angiogenesis was
assessed. Both VEGF and FGF-2 increased angiogenesis,
measured as CD31 expression either using p-nitrophenol
phosphate or as CD31 immuno-positive area (Figure 6). PPI-
Table 1
PPI-2458 reduces joint destruction in chronic collagen-induced arthritis
Arthritic changes Treatment
Untreated sTNF-RII PPI-2458
Normal 0 (0%) 3 (19%) 0 (0%)
Mild 2 (11%) 9 (56%) 13 (56%)
Moderate 12 (67%) 4 (25%) 10 (44%)
Severe 4 (22%) 0 (0%) 0 (0%)
Significance - P < 0.001 P < 0.01
Following onset of arthritis, mice were treated with either PPI-2458 (1.5 mg/kg every other day), soluble tumour necrosis factor receptor (sTNF-
R)II (5 mg/kg every other day), or vehicle alone for 28 days. Hematoxylin and eosin sections were scored in a blinded manner for pannus 
formation, synovitis, bone and cartilage erosion. Paws were assigned one of four grades: normal; mild synovitis with some loss of cartilage; 
moderate with more extensive synovial hyperplasia, destruction of cartilage and some bone erosions caused by an invasive pannus front; and 
finally severe, judged to have complete destruction of the joint architecture. Results are the number of paws exhibiting normal, mild, moderate and 
severe changes, with percentage in parentheses. Statistical analysis of raw data was carried out by χ2 test versus untreated mice.
Figure 4
PPI-2458 reduces joint destruction in chronic collagen-induced  arthritis PPI-2458 reduces joint destruction in chronic collagen-induced arthri-
tis. Following onset of arthritis, mice were treated with either PPI-2458 
(1.5 mg/kg every other day), soluble tumour necrosis factor receptor 
(sTNF-R)II (5 mg/kg every other day), or vehicle alone for 28 days. 
Hematoxylin and eosin sections were scored in a blinded manner for 
pannus formation, synovitis, bone and cartilage erosion. Representative 
images, with bar equivalent to 20 μm, are illustrated.Arthritis Research & Therapy    Vol 9 No 6    Bainbridge et al.
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2458 at 1 nmol/l and 10 nmol/l significantly reduced angio-
genesis induced both by VEGF and FGF-2 (Figure 6a–c). Vis-
ualization of the endothelial network confirmed these results,
with tubule formation being far less extensive following PPI-
2458 and fumagillin treatment compared with untreated con-
trols (Figure 6d).
In contrast, incubation of confluent HUVEC with PPI-2458
(0.01 to 10 nmol/l) was without effect on release of cytokines
in response to inflammatory stimuli (IL-1β, TNF-α, or LPS). This
is illustrated in Figure 7 for production of MCP-1. Comparable
results were obtained when release of IL-6 and IL-8 were
measured (data not shown).
PPI-2458 is without effect on RA synovial cell responses
To determine whether PPI-2458 might exert effects on cells in
RA synovium other than endothelial cells, RA synovial tissue
was enzymatically dissociated, and release of cytokines and
chemokines in the presence of increasing concentrations of
either fumagillin or PPI-2458 was measured. Spontaneous
productions of VEGF, IL-6, TNF-α and the chemokine MCP-1
were not affected at doses of PPI-2458 up to 10 nmol/l (Fig-
ure 8a–d). Comparable data were obtained when release of
IP-10, MIP-1α and IL-8 were assessed (data not shown). Cell
viability was also not affected in these studies (data not
shown).
Discussion
Endothelial cell proliferation is important in RA pathogenesis,
providing the foundation of leucocyte invasion, synovial inflam-
mation, pannus formation and bone destruction. Angiogenesis
has been implicated in the pathophysiology of RA. Further-
more, molecules with MetAP-2 inhibitory activity such as TNP-
470 and fumagillin can suppress disease in animal models,
possibly via inhibition of angiogenesis in vivo [31-34]. Previ-
ous studies have reported that established CIA, induced in
rats by chick collagen, was significantly reduced by treatment
with the MetAP-2 inhibitor AGM-470 [31-33]. AGM-1470
reduced joint destruction and vascularity, without affecting T-
cell function [34]. Similarly, in the KRN (K/BxN)/nonobese dia-
betic model of spontaneous murine arthritis, TNP-470 sup-
pressed disease when given early during the course of arthritis
[35]. In severe combined immunodeficient mice implanted
with human RA synovial tissue, the number of synovial lining
cells and blood vessel counts was markedly reduced by TNP-
470 compared with untreated animals. In parallel, proliferating
endothelial cells in the implanted synovial tissue were also
reduced by TNP-470 treatment [36].
In the present study, we utilized the acute CIA model in DBA/
1 mice, which was used to demonstrate efficacy of anti-TNF-α
antibody and which was the basis for the widespread clinical
use of TNF-α inhibitors for treatment of patients with RA [37-
40]. Acute murine CIA is thus an excellent predictive model in
which to study new therapeutic approaches for RA. In parallel,
we used a model of chronic CIA. Immunization of mice with
murine rather than bovine collagen leads to disease that more
closely resembles RA, supporting its use as a tool for testing
new therapies [27].
We report that PPI-2458, an inhibitor of MetAP-2, not only
inhibits acute CIA model but also has profound effect on the
pathology of chronic CIA. Although heterologous CIA
response is well known to involve predominantly a largely
Figure 5
PPI-2458 reduces proliferation of HUVEC PPI-2458 reduces proliferation of HUVEC. Human umbilical vein 
endothelial cells (HUVEC) were plated at 3 × 103 in 30 mm2 wells and 
stimulated with either (a) vascular endothelial growth factor (VEGF; 10 
ng/ml) or (b) fibroblast growth factor (FGF)-2 (50 ng/ml) in 10% foetal 
calf serum, or were left untreated (serum-free medium). Fumagillin (10 
nmol/l) and PPI-2458 (0.01 to 10 nmol/l) or 0.001% dimethyl sulfoxide 
as a vehicle control were added where indicated for 24 hours. Cells 
were pulsed with 10 μCi per well 3H-thymidine for a further 24 hours. 
Data are expressed as means ± standard deviation, representative of 
three experiments, and were analysed by one-way analysis of variance 
versus response in the absence of inhibitor: **P < 0.01.Available online http://arthritis-research.com/content/9/6/R127
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neutrophilic infiltrate, the success of PPI-2458 in ameliorating
disease progression provides evidence of the crucial role of
the vasculature in this model. Although all doses moderated
arthritis, the most pronounced response was at 1.5 mg/kg per
day, indicating that this was the optimal dose in this model.
Our results are also supported by a study using an alternative
model of arthritis, in which PPI-2458 was able to reduce paw
swelling in Lewis rats with peptidoglycan-polysaccharide
induced arthritis [28,41].
Whilst heterologous (bovine) CIA provides a tried and tested
mechanism for assessing therapeutics such as TNF-α inhibi-
tors [37-40], previous studies have shown that autologous
type II collagen can be used to produce a chronic relapsing
model with even greater relevance to RA [27,42]. The arthritis
in these animals fluctuates between disease and
improvement, involving with time an increasing number of
joints, with remissions becoming less frequent. Histological
findings indicate that the synovial infiltration comprises mostly
mononuclear cells and that the synovium is characterized by
an abundance of blood vessels, as is the case for RA. The use-
fulness of chronic CIA as a tool for testing new therapies is
substantiated by the observation that chronic CIA can distin-
guish between anti-inflammatory and disease-modifying
Figure 6
PPI-2458 reduces VEGF and FGF-2 mediated angiogenesis PPI-2458 reduces VEGF and FGF-2 mediated angiogenesis. Angiogenesis in response to either (a,b,d) 2 ng/ml vascular endothelial growth factor 
(VEGF) or (c) 50 ng/ml fibroblast growth factor (FGF)-2 was assessed after 11 days. Fumagillin (10 nmol/l) and PPI-2458 (1 nmol/l or 10 nmol/l), or 
0.001% dimethyl sulfoxide as a vehicle control were added where indicated. CD31 expression was measured using alkaline phosphatase-mediated 
conversion of (panel a) p-nitrophenol phosphate followed by colorimetric assay (panels b and c) BCIP/NBT (5-bromo-4-chloro-3-indolyl phosphate/
nitro blue tetrazolium) followed by image analysis. Data are expressed as means ± standatd deviation, representative of three experiments, and were 
analysed by one-way analysis of variance versus response in the absence of inhibitor: **P < 0.01. Included in panel d are representative images 
showing morphology of the formed tubes stained for CD31 at day 11 (objective magnification 40×).Arthritis Research & Therapy    Vol 9 No 6    Bainbridge et al.
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drugs. Indomethacin, a nonsteroidal anti-inflammatory drug
that fails to prevent radiological progression of RA, sup-
pressed the progression of disease and induced joint protec-
tion in acute CIA. In contrast, when used in chronic CIA,
indomethacin slowed clinical progression but failed to protect
against joint destruction [27]. Thus, chronic CIA is a useful
model for testing potential therapies for RA. Moreover, the
extensive vasculature network in this model [27] provides an
ideal platform for testing antiangiogenic agents. To determine
whether the efficacy of PPI-2458 in acute CIA translated also
to a chronic model of arthritis, which would more closely mimic
human RA, we investigated its effect in chronic CIA. In this
model, PPI-2458 consistently reduced disease severity and
joint destruction.
To evaluate further the mechanism of action of PPI-2458, the
effects of the MetAP-2 inhibitors on endothelial proliferation
and tubule formation induced by VEGF and FGF-2 were inves-
tigated. VEGF and FGF-2 are expressed in human RA and
increase endothelial angiogenesis [6,8,43,44]. The in vivo effi-
cacy of PPI-2458 in CIA was paralleled by significant inhibition
of  in vitro angiogenesis, which was observed as reduced
endothelial proliferation and tubule formation induced both by
VEGF and FGF-2. However, the anti-angiogenic effect of PPI-
2458 was not accompanied by a global inhibition of endothe-
lial cell responses, because release of cytokines and chemok-
ines by confluent HUVEC exposed to IL-1β, TNF-α, or LPS
was not affected at the same doses of PPI-2458. Furthermore,
PPI-2458 did not affect total RA synovial cell responses.
Release of IL-6 and VEGF from RA fibroblasts has been
shown to be unaffected by PPI-2458 [28]. However, in addi-
tion to the fibroblasts, many other cell types are present in RA
synovium, and these cells are also sources of proinflammatory
cytokines, particularly TNF-α in the case of macrophages. The
heterogeneous total RA synovial membrane cell culture
system was originally developed to examine the effectiveness
of TNF-α blockade in RA [45], and it has since been exten-
sively used to study synovial cell responses, including expres-
sion of angiogenic factors such as VEGF [6,46-49]. In this
model, release of chemokines (IL-8, MCP-1, IP-10 and MIP-
1α), cytokines (IL-6 and TNF-α) and growth factors (VEGF)
was unaffected by PPI-2458.
We have shown that long-term administration of PPI-2458
reduces chronic relapsing CIA, a model that has previously
been shown to mimic human RA, and to abolish endothelial
cell angiogenic responses to key mediators, namely VEGF and
FGF-2. Taken together, these results highlight that MetAP-2 is
a good candidate therapeutic intervention in RA. Although we
have not unequivocally demonstrated that angiogenesis is
inhibited by PPI-2458 in vivo, the in vitro findings suggest that
inhibition of MetAP-2 might translate to reduced blood vessel
formation in arthritic synovium. However, more detailed analy-
sis of synovial vascularity would be required to substantiate
this hypothesis.
Figure 7
PPI-2458 does not affect HUVEC inflammatory responses PPI-2458 does not affect HUVEC inflammatory responses. Human 
umbilical vein endothelial cells (HUVEC) were plated at 3 × 104 in 75 
mm2 wells and stimulated for 24 hours with either (a) IL-1β (10 ng/ml), 
(b) tumour necrosis factor (TNF)-α (10 ng/ml), or (c) lipopolysaccha-
ride (LPS; 500 ng/ml). Fumagillin (10 nmol/l) and PPI-2458 (0.01 to 10 
nmol/l), or 0.001% dimethyl sulfoxide as a vehicle control were added 
where indicated. Release of monocyte chemoattractant protein (MCP)-
1 was measured by enzyme-linked immunosorbent assay (ELISA). 
MCP-1 was measured by ELISA. Data are expressed as mean ± stand-
ard deviation, representative of at least three experiments.Available online http://arthritis-research.com/content/9/6/R127
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Conclusion
The chronic model of arthritis closely mimics that of RA and
hence is a potentially a good predictor of clinical efficacy. The
response in chronic CIA to MetAP-2 inhibition indicates that
PPI-2458 has therapeutic potential for future use in RA.
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